Home

Ind-swift Laboratories Ltd PE Ratio

Image

Ind-Swift Laboratories Ltd

NSE: INDSWFTLAB

PE

6

Last updated on: Jan 15, 2025

Key Highlights

  • The P/E Ratio of Ind-Swift Laboratories Ltd is 6 as of 15 Jan 9.00 AM .
  • The P/E Ratio of Ind-Swift Laboratories Ltd changed from 6.9 on March 2023 to 1.4 on March 2024 . This represents a CAGR of -54.96% over 2 years.
  • The Latest Trading Price of Ind-Swift Laboratories Ltd is ₹ 103.05 as of 14 Jan 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.4. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 36.9 in 2024.

Historical P/E Ratio of Ind-Swift Laboratories Ltd

No data available

Company Fundamentals for Ind-Swift Laboratories Ltd

Image

Ind-Swift Laboratories Ltd

NSE: INDSWFTLAB

Share Price

₹ 103.05

-2.10 (-2.00%)

stock direction

Last updated on: Jan 14, 2025

Market Price of Ind-Swift Laboratories Ltd

1M

1Y

3Y

5Y

Monitoring Ind-Swift Laboratories Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
14 Jan 2025103.05
13 Jan 2025105.15
10 Jan 2025107.25
09 Jan 2025109.4
08 Jan 2025111.6
07 Jan 2025109.5
06 Jan 2025110.15
03 Jan 2025112.35
02 Jan 2025110.2
01 Jan 2025111.85

SWOT Analysis Of Ind-Swift Laboratories Ltd

Strength

5

che

Weakness

2

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Ind-Swift Laboratories Ltd

Asset Value vs Market Value of Ind-Swift Laboratories Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Ind-Swift Laboratories Ltd608.89
Sun Pharmaceuticals Industries Ltd424382
Divis Laboratories Ltd159224
Cipla Ltd116943
Dr Reddys Laboratories Ltd111588

PE Ratio of Ind-Swift Laboratories Ltd Explained

``

608.89

Market cap

373

Earnings

6.0X

PE Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Ind-Swift Laboratories Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Ind-Swift Laboratories Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Ind-Swift Laboratories Ltd

No data available

* All values are in %

About Ind-Swift Laboratories Ltd

  • Ind-Swift Laboratories Limited is a part of the Ind-Swift Group and is based at Chandigarh, India.
  • The Company is one of the leading manufacturers of APIs catering to global and domestic formulators.
  • Based in Chandigarh, India, the Company operated two advanced manufacturing facilities in Derabassi and Jammu, adhering to international standards.
  • Ind-Swift Laboratories Ltd. is recognised globally as a leader in the Macrolide Antibiotic sector, and its products are well-regarded by major pharmaceutical formulators worldwide. Ind-Swift Laboratories Limited was incorporated on January 4, 1995 as a joint venture between Ind-Swift Ltd and Punjab State Industrial Development Corporation.
  • Later, Ind-Swift purchased Punjab State Industrial Development Corporation equity to emerge as a single largest shareholder in the company.

Ind-Swift Laboratories Ltd News Hub

Ind-Swift Laboratories consolidated net profit declines 94.55% in the June 2024 quarter

Net profit of Ind-Swift Laboratories declined 94.55% to Rs 0.94 crore in the quarter ended June 2024

Read more

2024-08-13 00:00:00

Ind-Swift Laboratories standalone net profit declines 63.70% in the June 2024 quarter

Net profit of Ind-Swift Laboratories declined 63.70% to Rs 6.19 crore in the quarter ended June 2024

Read more

2024-08-13 00:00:00

Ind-Swift Laboratories to discuss results

Ind-Swift Laboratories will hold a meeting of the Board of Directors of the Company on 12 August 202

Read more

2024-08-03 00:00:00

Ind-Swift Laboratories to hold AGM

Ind-Swift Laboratories announced that the Annual General Meeting (AGM) of the company will be held o

Read more

2024-09-03 00:00:00

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Ind-Swift Laboratories Ltd

What is the current PE Ratio of Ind-Swift Laboratories Ltd?

The Current PE Ratio of Ind-Swift Laboratories Ltd is 5.96 as on 15 Jan 2025.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 15 Jan 2025.

What was the PE Ratio of Ind-Swift Laboratories Ltd last year?

The PE Ratio of Ind-Swift Laboratories Ltd was 6.94 last year, now the PE ratio is 5.96, showing a year-on-year growth of -14.1%.

What does the PE Ratio of Ind-Swift Laboratories Ltd indicate about its stock?

The PE Ratio of Ind-Swift Laboratories Ltd is 5.96. This ratio indicates that investors are willing to pay 5.96 times the earnings per share for each share of Ind-Swift Laboratories Ltd.

What is the PE Ratio Growth of Ind-Swift Laboratories Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Ind-Swift Laboratories Ltd grew by -14.1% whereas, the EPS ratio grew by -56.3.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions